822
BACKGROUND: Etanercept is a tumor necrosis factor (TNF) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis.
 ( potential therapeutic event: licensed ,  adult and juvenile rheumatoid arthritis as well as psoriatic arthritis: Subject, adult: Subject.Age, juvenile: Subject.Age, Etanercept: Treatment, a tumor necrosis factor (TNF) inhibitor: Treatment, Etanercept: Treatment.Drug, adult and juvenile rheumatoid arthritis: Treatment.Disorder, psoriatic arthritis: Treatment.Disorder) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: licensed ,  adult and juvenile rheumatoid arthritis as well as psoriatic arthritis: Subject, adult: Subject.Age, juvenile: Subject.Age, Etanercept: Treatment, a tumor necrosis factor (TNF) inhibitor: Treatment, Etanercept: Treatment.Drug, adult and juvenile rheumatoid arthritis: Treatment.Disorder, psoriatic arthritis: Treatment.Disorder) 